KKR Expands into Biopharma Royalties with HCRx Acquisition

In a strategic move to bolster its presence in the biopharmaceutical sector, KKR & Co. Inc. announced on Wednesday its acquisition of a majority stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company.

Leadership and Collaboration

Under the terms of the agreement, Clarke Futch, CEO and Chairman of HCRx, will continue to lead the team, fostering close collaboration with KKR's healthcare unit to innovate financial solutions within the biopharma division. This partnership is set to enhance KKR's expertise in biopharma royalty and credit investing.

A Strategic Partnership

"Our decision to invest in HCRx was driven by our longstanding relationship with the firm, its pioneering role in the biopharma royalties market—a sector experiencing increasing demand—and the exceptional leadership team," remarked Ali Satvat, Partner Co-Head of Health Care and Global Head of Health Care Strategic Growth at KKR. "We are excited about the unique platform Clarke and the HCRx team have developed and are thrilled to welcome them to the KKR family."